JAL4 Antibody
Description
Identification of JAL Antigen and Associated Antibodies
The JAL antigen (ISBT: RH48) is a rare blood group antigen first identified in 1990. It occurs in two primary haplotypes:
-
(C)(e) haplotype: Found in Caucasians, associated with weakened C, e, hr<sup>B</sup>, and hr<sup>S</sup> antigen expression.
-
(c)(e) haplotype: Predominant in individuals of Black African ancestry, linked to reduced c, e, f, V, VS, hr<sup>B</sup>, and hr<sup>S</sup> antigen expression .
Key serological characteristics:
| Feature | Observation |
|---|---|
| Antigen prevalence | <0.1% in global population |
| Antibody type | Alloanti-JAL (IgG class) |
| Clinical impact | Hemolytic disease of the fetus/newborn (HDFN), transfusion reactions |
Anti-JAL Antibody Characteristics
Anti-JAL antibodies are clinically significant due to their ability to target the high-prevalence CEST antigen (antithetical to JAL). Key findings include:
Serological Behavior
-
Cross-reactivity: Anti-JAL antibodies may mimic anti-Rh17 specificity in some cases .
-
Dosage effect: Antibody reactivity varies with antigen density on red blood cells (RBCs).
Genetic and Molecular Insights
| Haplotype | Affected Antigens | Ethnic Association |
|---|---|---|
| (C)(e) | Weakened C, e, hr<sup>B</sup>, hr<sup>S</sup> | Caucasian |
| (c)(e) | Weakened c, e, f, V, VS, hr<sup>B</sup> | Black African ancestry |
Source: Lomas et al. (1990) extended studies
Hemolytic Disease of the Newborn (HDN)
-
Case studies: Anti-JAL has been implicated in severe HDN requiring intrauterine transfusions .
-
Management: Requires antigen-negative blood for transfusions and antenatal monitoring.
Transfusion Challenges
-
Frequency: Anti-JAL causes <1% of all hemolytic transfusion reactions.
-
Detection: Requires specialized immunohematology testing due to low antigen prevalence .
Research Gaps and Future Directions
While anti-JAL antibodies are well-characterized, no studies explicitly reference "JAL4" as a distinct entity. Potential areas for investigation:
-
Molecular basis of JAL antigen variation across haplotypes.
-
Development of recombinant antigens for improved antibody detection.
-
Long-term outcomes of anti-JAL-mediated HDN.
Product Specs
Composition: 50% Glycerol, 0.01M PBS, pH 7.4
Q&A
Here’s a structured collection of FAQs tailored for academic researchers studying the JAL4 Antibody, synthesized from peer-reviewed studies and technical reports. Questions are categorized into basic and advanced tiers, with methodological guidance and supporting data.
How to validate JAL4 Antibody specificity in serologic assays?
Methodological Answer:
-
Use hemagglutination assays with red blood cells (RBCs) expressing JAL (RH48) and controls lacking the antigen. Include multiple anti-JAL sources (e.g., J. Pas., S. Allen, J. McD) to confirm reactivity .
-
Validate using flow cytometry for membrane-bound antibody detection, as demonstrated in studies expressing JAL4 on transfected 293 cells .
-
Cross-check with Rh antigen-depleted RBCs to rule out cross-reactivity (e.g., weakened C, c, e antigens in JAL+ samples) .
Key Data Table (Rh Antigen Weakening in JAL+ Haplotypes):
| Haplotype | Weakened Antigens | Population | Source |
|---|---|---|---|
| (C)(e) | C, e, hrB, hrS | Caucasian | |
| (c)(e) | c, e, f, V, VS, hrB, hrS | Black African |
What experimental models are suitable for studying JAL4 Antibody interactions?
Methodological Answer:
-
In vitro: Use transfected cell lines (e.g., FreeStyle 293 cells) expressing JAL4 epitopes to study antibody binding kinetics .
-
Clinical cohorts: Analyze RBCs from JAL+ individuals with hemolytic disease of the newborn (HDN) to assess antibody pathogenicity .
-
Structural studies: Employ hydrogen-deuterium exchange mass spectrometry (HDX-MS) to map JAL4 epitopes, as done for SARS-CoV-2 NTD-targeting antibodies .
How to detect JAL4-associated antigen weakening in Rh blood group systems?
Methodological Answer:
-
Quantify antigen density via flow cytometry using fluorophore-conjugated anti-C, anti-e, or anti-hrB antibodies .
-
Compare JAL+ samples to JAL– controls using hemagglutination titration scores (e.g., weakened e antigen reactivity in Table 2 of ).
Advanced Research Questions
Methodological Answer:
-
Investigate steric hindrance using cryo-EM to visualize JAL4 binding proximity to Rh antigens (e.g., NTD crosslinking in SARS-CoV-2 spikes) .
-
Perform gene-editing studies (CRISPR/Cas9) to assess JAL4’s effect on RHAG/RHCE transcript stability .
How to design functional screens for JAL4-like antibodies with broad reactivity?
Methodological Answer:
-
Adapt high-throughput antibody display systems (e.g., Venus-tagged plasmids in 293 cells) .
-
Use multiplexed antigen probes (e.g., Alexa647-H1 + Alexa568-H2) to test cross-reactivity .
Screening Workflow:
